New drug combo for HER2-positive breast cancer before surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have HER2-positive breast cancer that has not spread to other parts of the body.
- Your tumor is larger than 2 cm or has spread to the lymph nodes under your arm.
- You have not had chemotherapy, hormone therapy, or targeted therapy for this breast cancer before.
- You do not have a serious heart condition, and your heart function is normal (LVEF at least 50%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new HER2-targeted antibody drug (TQB2102) against standard chemotherapy in people with HER2-low breast cancer that has spread or come back. It aims to see if the new drug works better or is safer than usual chemotherapy.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.